NASDAQ · REGN
Healthcare · Biotechnology
$746.54
Up+$6.97 (+0.94%)
Updated Oct 10, 2026, 4:52 PM
SID Score
6.0/10
Composite research score
Smart Money
59/100
Neutral
Price performance · REGN
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 9, 2026
REGN closed at $746.54 after 21 trading sessions, down 4.47% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 9, 2026 | $737.20 | $751.27 | $732.83 | $746.54 | 466.03K |
| Oct 8, 2026 | $742.12 | $744.50 | $723.647 | $739.57 | 500.3K |
| Oct 7, 2026 | $738.05 | $753.68 | $734.18 | $742.12 | 626.43K |
| Oct 6, 2026 | $734.61 | $740.51 | $727.155 | $738.72 | 615.06K |
| Oct 5, 2026 | $734.365 | $736.42 | $722.02 | $726.47 | 695.03K |
| Oct 2, 2026 | $740.50 | $742.50 | $729.1983 | $735.20 | 613.95K |
| Oct 1, 2026 | $766.53 | $777.43 | $726.02 | $734.81 | 1.04M |
| Sep 30, 2026 | $749.84 | $763.72 | $742.94 | $758.27 | 872.46K |
| Sep 29, 2026 | $745.85 | $752.47 | $741.829 | $750.51 | 804.34K |
| Sep 28, 2026 | $778.09 | $780.945 | $750.00 | $752.25 | 1.15M |
| Sep 25, 2026 | $803.87 | $803.87 | $784.13 | $788.04 | 592.15K |
| Sep 24, 2026 | $801.59 | $807.205 | $789.39 | $796.02 | 602.65K |
| Sep 23, 2026 | $805.23 | $813.53 | $790.02 | $801.82 | 721.11K |
| Sep 22, 2026 | $802.48 | $811.6599 | $791.31 | $803.90 | 600.27K |
| Sep 21, 2026 | $786.03 | $801.44 | $779.96 | $798.17 | 704.53K |
| Sep 18, 2026 | $787.34 | $794.73 | $779.65 | $784.85 | 2.47M |
| Sep 17, 2026 | $781.18 | $789.99 | $774.775 | $789.45 | 702.82K |
| Sep 16, 2026 | $775.82 | $779.98 | $771.8001 | $774.61 | 382.95K |
| Sep 15, 2026 | $788.53 | $788.58 | $769.5725 | $774.11 | 540.84K |
| Sep 14, 2026 | $791.98 | $798.8352 | $779.45 | $793.74 | 591.3K |
| Sep 11, 2026 | $800.00 | $800.22 | $780.81 | $781.49 | 443.99K |
The latest Smart Investors Daily articles mentioning REGN.
Company
Market Activity
Research & News
REGN research
Company profile and research snapshot.
Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has early-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Oct 8, 2026 | RBC Capital | Sector Perform | — |
| Oct 7, 2026 | Morgan Stanley | Equal-Weight | — |
| Oct 7, 2026 | Truist Securities | Buy | — |
| Oct 6, 2026 | JP Morgan | Overweight | — |
| Oct 1, 2026 | Argus Research | Buy | — |
No generated briefing is available yet.
Yahoo · Aug 1, 2026
Biotech company Regeneron (NASDAQ:REGN) reported revenue ahead of Wall Street’s expectations in Q2 CY2026, with sales up 16.7% year on year to $4.29 billion. Its non-GAAP profit of $14.29 per share was 40.1% above analysts’ consensus estimates.
Benzinga · Jul 31, 2026
RBC Capital analyst Brian Abrahams maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Sector Perform and raises the price target from $696 to $737.
Yahoo · Jul 31, 2026
AbbVie shares took a hit Friday after costs related to the drugmaker’s acquisition of Apogee Therapeutics forced a cut to its full-year profit outlook. Second-quarter revenue jumped 10% to nearly $17 billion, beating the $16.8 billion consensus estimate among analysts polled by FactSet. AbbVie posted adjusted earnings of $3.65 a share, narrowly ahead of Wall Street’s call for $3.60.
Benzinga · Jul 31, 2026
Morgan Stanley analyst Matthew Harrison maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Equal-Weight and raises the price target from $730 to $758.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning REGN.
